The company has successfully completed a directed share issue, which will provide it with a gross proceed of approximately SEK 324 million.
The board of directors of Immunovia has resolved on a directed share issue of 2,162,794 new shares at a subscription price of SEK 150 per share. The subscription price in the Share Issue corresponds to a discount of 9 percent compared to the closing price on June 7, 2018. The Share Issue generated strong demand from institutions in Sweden and internationally, such as Swedbank Robur, Handelsbanken Fonder, Alfred Berg Kapitalförvaltning AB, Nyenburgh Investment Partners, Apus Capital and Bonit Capital.
Money to accelerate
Immunovia intends to use the net proceeds from the Share Issue to accelerate previously announced launching preparations and build a US sales and key account organization. It also intends to use to money for marketing campaigns and other sales efforts, as well as further investments in the company’s product development platform.